Which stock wins in a matchup between these two successful biotechs?
News & Analysis: Galapagos
The Belgian biopharma bagged $5.1 billion from its most important partner.
GLPG earnings call for the period ending June 30, 2019.
Here's what Gilead's getting with its $5.1 billion Galapagos collaboration.
Despite already massive gains this year, shares of these drugmakers could keep on climbing.
From failed takeover talks to a massive new partnership, see why these stocks were on the move on a quiet day for the broader markets.
Gilead Sciences decided to inject $5.1 billion into its R&D partner Galapagos NV over the weekend.
The good news keeps rolling in for this Belgian pharma.
Two rising biotech stocks. One clear long-term winner.
GLPG earnings call for the period ending March 31, 2019.